ClinicalTrials.gg
CompletedNCT00803790Updated Feb 3, 2022Results posted

A Study of the Bioequivalence of 70-mg Alendronate and 70-mg Alendronate in Combination With 5600 IU Vitamin D (MK0217A-253)

A Phase 1 interventional study of alendronate sodium+vitamin D combination and Comparator: alendronate in Osteoporosis, sponsored by Organon and Co. Completed. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-03.

Sponsored by Organon and Co · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
318
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies testing alendronate in Osteoporosis — 2 open to participants now, 4 under way, none of them phase 3. Alendronate · Osteoporosis.

Enrollment
5th of 51
318 · median 60
Started
2006
with 4 others
Phase 1
2 of 51
none open now
Registered
27th of 51
by date
Lead sponsor
2 of 51
Organon and Co

Among the 51 studies testing alendronate in Osteoporosis, this one is the 5th largest by enrollment, is one of 5 that started in 2006, is one of 2 in phase 1, and was the 27th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

2 of the 51 studies testing alendronate in Osteoporosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About alendronate

Alendronate: first FDA approval 1995 (FOSAMAX), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing alendronate in Osteoporosis, or all of them as a file.
02

Study summary

This study will evaluate the bioequivalence of alendronate in combination with vitamin D compared to alendronate alone and the bioequivalence of vitamin D in combination with alendronate compared to vitamin D alone.

This was an open-label, randomized, 2-part, crossover study. Each participant participated in one part of the study only (i.e., each participant participated only in Part I or only in Part II). Participants entered the study sequentially within each part of the study. A washout of at least 12 days separated each treatment period within each part of the study.

03

Conditions studied

  • Osteoporosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or nonpregnant female age 18 to 85 years
  • female of on appropriate method of and not nursing
  • (BMI) less than or equal to 30 kg/m2
  • subject is in good health

Exclusion criteria

Exclusion Criteria:

  • mental or legal incapacitation
  • received bisphosphonate treatment within 3 months of enrollment.
  • unable to sit or stand upright for at least 2 hours
  • unwilling to refrain from consumption of alcohol or caffeinated products from 24 hours prior and 36 hours after study drug administration
  • unwilling to limit alcohol consumption to no more than 2 drinks per day
  • unwilling to limit caffeinated products to the equivalent of 4 cups of coffee per day or equivalent.
  • unwilling to refrain from smoking during the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
318 participants (actual)

Study arms

  • Experimental
    Sequence 1- alendronate+vitamin D combination then alendronate

    Participants in Part 1 received 70mg alendronate+5600 International Units (IU) vitamin D combination tablet in Period 1 followed by 70mg alendronate tablet in Period 2. A washout of at least 12 days separated each treatment period.

    Drug: alendronate sodium+vitamin D combination · Drug: Comparator: alendronate

  • Experimental
    Sequence 2 alendronate then alendronate+vitamin D combination

    Participants in Part 1 received 70mg alendronate tablet in Period 1 followed by 70mg alendronate+5600 IU vitamin D combination tablet in Period 2. A washout of at least 12 days separated each treatment period.

    Drug: alendronate sodium+vitamin D combination · Drug: Comparator: alendronate

  • Experimental
    Sequence 3 alendronate+vitamin D combination then vitamin D

    Participants in Part 2 received 70mg alendronate+5600 IU vitamin D combination tablet in Period 1 followed by a single dose of 5600 IU vitamin D, administered as two 2800 IU tablets in Period 2. A washout of at least 12 days separated each treatment period.

    Drug: alendronate sodium+vitamin D combination · Dietary Supplement: Comparator: Vitamin D

  • Experimental
    Sequence 4- vitamin D then alendronate+vitamin D combination

    Participants in Part 2 received a single dose of 5600 IU vitamin D, administered as two 2800 IU tablets in Period 1 followed by a 70mg alendronate+5600 IU vitamin D combination tablet in Period 2. A washout of at least 12 days separated each treatment period.

    Drug: alendronate sodium+vitamin D combination · Dietary Supplement: Comparator: Vitamin D

Interventions

  • Drugalendronate sodium+vitamin D combination

    Drug pages: Alendronate · Vitamin D

    A single dose tablet of 70mg alendronate sodium+5600 IU vitamin D combination tablet in one treatment period of each sequence.

  • A single dose tablet of 70mg alendronate in one treatment period of each sequence.

  • Dietary supplementComparator: Vitamin D

    Two tablets of 2800 IU vitamin D, totaling 5600 IU, in one treatment period of each sequence.

06

What researchers measure

Primary outcomes

  1. Part 1: Urinary Excretion of Alendronate

    Bioequivalence was demonstrated by measuring the total urinary excretion of alendronate which was determined over a 36-hour period following single dose administration of 70-mg alendronate+5600 International Units (IU) vitamin D combination tablet and 70mg alendronate tablet alone. Urine for each treatment period was collected at -2 to 0 hours predose, 0 to 8, 8 to 24, and 24 to 36 hours postdose on Days 1 and 2.

    Time frame: Day 1-2 across the 36 hour urinary collection period (Periods 1 and 2)

  2. Part II: AUC (Area Under the Plasma Concentration-time Curve) of Vitamin D

    The serum vitamin D pharmacokinetic parameter was calculated following the treatment of 70mg alendronate+5600 IU vitamin D combination tablet and 5600 IU vitamin D tablet on Day 1: area under the plasma concentration-time curve (AUC0-80hr). Serum samples for determination of vitamin D concentrations were obtained at -2 and 0 hrs predose on Day 1 and at 2, 3, 5, 7, 9, 12, 16, 24, 36, 48, 72 and 80 hours post dose for each treatment period.

    Time frame: Day 1 across the 80-hour plasma collection period (Period 1 and 2)

Secondary outcomes

  1. Part II : Maximum Concentration (Cmax) of Vitamin D

    Serum vitamin D pharmacokinetic parameter was calculated for the following: maximum concentration of drug observed in serum (Cmax). Serum samples for determination of vitamin D concentrations were obtained at -2 and 0 hrs predose on Day 1 and at 2, 3, 5, 7, 9, 12, 16, 24, 36, 48, 72 and 80 hours post dose for each treatment period.

    Time frame: Day 1 across the 80-hour plasma collection period (Periods 1 and 2)

07

Results

Posted May 9, 2011

Participant flow

Period 1
Participant flow — Period 1
MilestonePart 1 Alendronate+Vitamin D Combo, Then AlendronatePart 1 Alendronate, Then Alendronate+Vitamin D ComboPart 2 Alendronate+Vitamin D Combo, Then Vitamin DPart 2 Vitamin D, Then Alendronate+Vitamin D Combo
Started1251263235
Completed1161143131
Not completed91214
Withdrew: Adverse event0100
Withdrew: Lost to follow-up1200
Withdrew: Withdrawal by subject8600
Withdrew: Positive drug screen or personal reasons0304
Withdrew: Protocol violation0010
Period 2
Participant flow — Period 2
MilestonePart 1 Alendronate+Vitamin D Combo, Then AlendronatePart 1 Alendronate, Then Alendronate+Vitamin D ComboPart 2 Alendronate+Vitamin D Combo, Then Vitamin DPart 2 Vitamin D, Then Alendronate+Vitamin D Combo
Started1161143131
Completed1141143030
Not completed2011
Withdrew: Adverse event0011
Withdrew: Withdrawal by subject1000
Withdrew: Positive drug screen or personal reasons1000

Outcome measures

PrimaryPart 1: Urinary Excretion of Alendronate

Bioequivalence was demonstrated by measuring the total urinary excretion of alendronate which was determined over a 36-hour period following single dose administration of 70-mg alendronate+5600 International Units (IU) vitamin D combination tablet and 70mg alendronate tablet alone. Urine for each treatment period was collected at -2 to 0 hours predose, 0 to 8, 8 to 24, and 24 to 36 hours postdose on Days 1 and 2.

Time frame:
Day 1-2 across the 36 hour urinary collection period (Periods 1 and 2)
Reported as:
Least squares mean · μg
Part 1: Urinary Excretion of Alendronate
μgAlendronate+Vitamin D ComboAlendronate
Part 1: Urinary Excretion of Alendronate133.6 ± 189.2132.2 ± 273.4
Statistical analysis
  • Alendronate+Vitamin D Combo vs Alendronate · Least square mean ratio: 1.01 · 90% CI 0.92 to 1.11
PrimaryPart II: AUC (Area Under the Plasma Concentration-time Curve) of Vitamin D

The serum vitamin D pharmacokinetic parameter was calculated following the treatment of 70mg alendronate+5600 IU vitamin D combination tablet and 5600 IU vitamin D tablet on Day 1: area under the plasma concentration-time curve (AUC0-80hr). Serum samples for determination of vitamin D concentrations were obtained at -2 and 0 hrs predose on Day 1 and at 2, 3, 5, 7, 9, 12, 16, 24, 36, 48, 72 and 80 hours post dose for each treatment period.

Time frame:
Day 1 across the 80-hour plasma collection period (Period 1 and 2)
Reported as:
Least squares mean · ng*hr/mL
Part II: AUC (Area Under the Plasma Concentration-time Curve) of Vitamin D
ng*hr/mLAlendronate+Vitamin D ComboVitamin D
Part II: AUC (Area Under the Plasma Concentration-time Curve) of Vitamin D490.2 ± 259.6518.7 ± 269.8
Statistical analysis
  • Alendronate+Vitamin D Combo vs Vitamin D · Least square mean ratio: 0.94 · 90% CI 0.89 to 1.00
SecondaryPart II : Maximum Concentration (Cmax) of Vitamin D

Serum vitamin D pharmacokinetic parameter was calculated for the following: maximum concentration of drug observed in serum (Cmax). Serum samples for determination of vitamin D concentrations were obtained at -2 and 0 hrs predose on Day 1 and at 2, 3, 5, 7, 9, 12, 16, 24, 36, 48, 72 and 80 hours post dose for each treatment period.

Time frame:
Day 1 across the 80-hour plasma collection period (Periods 1 and 2)
Reported as:
Least squares mean · ng/ml
Part II : Maximum Concentration (Cmax) of Vitamin D
ng/mlAlendronate+Vitamin D ComboVitamin D
Part II : Maximum Concentration (Cmax) of Vitamin D12.2 ± 5.613.0 ± 5.9
Statistical analysis
  • Alendronate+Vitamin D Combo vs Vitamin D · Least square mean ratio: 0.94 · 90% CI 0.88 to 1.00

Adverse events

Collected over 8 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alendronate+Vitamin D Combo—0/302 (0%)21/302 (7%)
Alendronate—0/241 (0%)12/241 (5%)
Vitamin D—0/65 (0%)9/65 (13.8%)
Most frequent other events
Most frequent other events
EventAlendronate+Vitamin D ComboAlendronateVitamin D
HeadacheNervous system disorders21/30212/2419/65

Baseline characteristics

Age, Customized
Age, Customized(participants)Part 1Part 2Total
Between 18 and 78 years25167318
Sex: Female, Male
Sex: Female, Male(Participants)Part 1Part 2Total
Female13229161
Male11938157
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Denker AE, Lazarus N, Porras A, Ramakrishnan R, Constanzer M, Scott BB, Chavez-Eng C, Woolf E, Maganti L, Larson P, Gottesdiener K, Wagner JA. Bioavailability of alendronate and vitamin D(3) in an alendronate/vitamin D(3) combination tablet. J Clin Pharmacol. 2011 Oct;51(10):1439-48. doi: 10.1177/0091270010382010. Epub 2010 Dec 8. PubMed 21148044 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Jul 2006 and a completion of Jul 2006. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 4 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2008
First posted
Dec 8, 2008
Start
May 2006
Primary completionActual
Jul 2006
CompletionActual
Jul 2006
Results first posted
May 9, 2011
Last update
Feb 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00803790
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Dec 8, 2008
Start date
May 2006
Primary completion
Jul 2006
Completion
Jul 2006
Results posted
May 9, 2011
Last update
Feb 3, 2022

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alendronate · Vitamin D

Start the discussion